Singapore (January 20, 2015) – Vela Diagnostics announced today the launch of the Sentosa® SQ Hepatitis C Virus (HCV) Genotyping Next-Generation Sequencing (NGS) Assay, the first assay of its NGS virology portfolio. The Sentosa® SQ HCV Genotyping NGS Assay is available for Research Use Only.
The Sentosa® SQ HCV Genotyping Assay detects genotypes 1, 2, 3, 4, 5 and 6, and subtypes 1a and 1b by targeting NS3, NS5A and NS5B regions; it exhibits a Limit of Detection (LOD) of 1000 IU/mL for genotypes 1a, 1b, 2, 3 and 4, and 2000 IU/mL for genotypes 5 and 6.
The Sentosa® SQ HCV Genotyping Assay is designed for use on the automated Sentosa® NGS workflow that consists of the Sentosa® SX101 automated pipetting system enabling automated DNA extraction and library set-up, and the NGS system. The NGS system comprises the Sentosa® ST401 instruments for automated template preparation, the Sentosa® SQ301 sequencer and server, as well as the Sentosa® SQ Reporter for efficient data analysis and report generation.
The automated Sentosa® NGS workflow offers computerized reporting and enables rapid and accurate genotyping across the complex HCV genome, hence increasing efficiency and reducing costs. The easy-to-interpret report format includes automated bioinformatics and results interpretation. The Sentosa® NGS workflow also promotes seamless sample tracking and network connectivity to ease information transfer and sample traceability.
Vela Diagnostics offers automated platforms that support both NGS and PCR workflows. The workflows share the Sentosa® SX101 automated pipetting system thereby increasing efficiency and flexibility. Three additional NGS panels are planned for 2015. About Vela Diagnostics Vela Diagnostics is a worldwide provider of integrated molecular diagnostics workflows that address individual testing needs. Established in 2011 with its global headquarters in Singapore, Vela Diagnostics provides innovative test and data reporting solutions for Real-Time PCR and Next-Generation Sequencing. Integrating both PCR and NGS solutions to test for infectious diseases and oncologic targets increases flexibility and efficiency of the workflow and enables laboratories to overcome complex diagnostic challenges. Reliable and multi-purpose instruments help reduce the cost for optimal efficiency across laboratories of all sizes. With scalability and open-channel capabilities, laboratories also benefit from the flexibility and versatility of the systems available. For more information, please visit www.veladx.com.
Media Contact
Esther Chew
Marketing Communications Manager
esther.chew@veladx.com
+65 6690 6016
Help employers find you! Check out all the jobs and post your resume.
